Nolato ABFRA:NBF +6.95%82 EBITDA Margin % is 10.61% as of Mar. 2026, which is 30% below its 10-year median of 15.07. GuruFocus rates FRA:NBF with a GF Score™ of 82/100 and a GF Value™ of €5.00 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Nolato AB ranks better than 57.23% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nolato AB's EBITDA for the
three
months ended in Mar. 2026 was €23.2 Mil. Nolato AB's Revenue for the
three
months ended in Mar. 2026 was €218.8 Mil. Therefore, Nolato AB's EBITDA margin for the quarter that ended in Mar. 2026 was 10.61%.
Nolato AB (FRA:NBF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nolato AB EBITDA Margin % Related Terms
Nolato AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nolato AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NBF vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Nolato AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nolato AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nolato AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nolato AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nolato AB (FRA:NBF) has a EBITDA Margin % of 10.61% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nolato AB and its competitors. This is 30% below median its historical median of 15.07. Over the past decade, Nolato AB's EBITDA Margin % has ranged from 10.83 to 16.87. According to the industry distribution chart, Nolato AB ranks #349 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 42.8%.
Is Nolato AB's EBITDA Margin % too high?
Nolato AB's current EBITDA Margin % of 10.61% is 30% below median its 10-year median of 15.07. Over the past 10 years, this metric has ranged from a low of 10.83 to a high of 16.87. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Nolato AB's value of 10.61% is 41.9% above this industry median. Based on the distribution chart, Nolato AB ranks #349 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nolato AB has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nolato AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nolato AB ranks #349 out of 816 companies for EBITDA Margin %. This puts Nolato AB in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Nolato AB's value of 10.61% is 41.9% above this benchmark. Historically, Nolato AB's own EBITDA Margin % has ranged from 10.83 to 16.87 over the past decade. While the company's 10-year median is 15.07 vs. the industry median of 7.48, Nolato AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nolato AB's current EBITDA Margin % of 10.61% is 41.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nolato AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nolato AB's current EBITDA Margin % is 10.61%, which is 30% below median its own 10-year median of 15.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nolato AB stock overvalued right now?
Based on GuruFocus' analysis, Nolato AB (FRA:NBF) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.00, compared to a current price of €4.47 — trading 10.7% below its estimated fair value. The current EBITDA Margin % is 10.61%, which is 30% below median its 10-year median of 15.07 and 41.9% above the Medical Devices & Instruments industry median of 7.48. Nolato AB's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nolato AB (FRA:NBF), the current EBITDA Margin % is 10.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nolato AB (FRA:NBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nolato AB stock appears to be undervalued.
The current stock price of €4.47 is trading 10.7% below its estimated GF Value™ of €5.00.
GuruFocus considers Nolato AB to be Modestly Undervalued.
Key valuation signals for FRA:NBF:
EBITDA Margin %: 10.61% (30% below median its 10-year median of 15.07)
GF Value™: €5.00 vs. price of €4.47 (10.7% below fair value)
Industry Position: 41.9% above the Medical Devices & Instruments median (#349 of 816)
No single metric tells the full story. See the FRA:NBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nolato AB is a Swedish company that develops and manufactures plastic, silicone, and thermoplastic elastomer products. The firm's operations are organized into two segments: Medical Solutions and Engineered Solutions. The company generates the majority of its revenue from the Medical Solutions segment, which is engaged in the development and manufacture of complex product systems and components for medical devices, the pharmaceutical industry, and diagnostics. The Engineered Solutions design, development, industrialization, and manufacture of subsystems and ready-packaged products for a range of industries, including offerings within EMC and thermal solutions. Geographically, the firm generates key revenue from the Rest of Europe and the United States.
82GF Score
Get the complete analysis for FRA:NBF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NBF has been successfully added to your 
